Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Inhibikase Therapeutics Inc (IKT) USD0.001

Sell:$2.26 Buy:$2.28 Change: $0.1 (4.22%)
Market closed |  Prices as at close on 30 July 2021 | Switch to live prices |
Change: $0.1 (4.22%)
Market closed |  Prices as at close on 30 July 2021 | Switch to live prices |
Change: $0.1 (4.22%)
Market closed |  Prices as at close on 30 July 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Inhibikase Therapeutics Inc. is a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The Company’s lead product candidate, IkT-148009 is for the treatment of PD, and for the treatment of gastrointestinal (GI), complications that arise as early symptoms of PD in patients. The Company’s kT-148009, is a brain penetrant c-Abl protein kinase inhibitor that halts disease progression and reverses functional loss in the brain and reverses neurological dysfunction in the GI tract. The Company’s products candidate also include IKT-001Pro, which is a prodrug of the anticancer agent Imatinib, and used as a treatment for stable-phase chronic myelogenous leukemia (CML), and IKT-01427 for progressive multifocal leukoencephalopathy (PML).

Contact details

3350 Riverwood Parkway Se, Suite 1900
United States
+1 (678) 3923419

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$57.30 million
Shares in issue:
25.13 million
United States
US dollar

Key personnel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.